Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Operating Expenses (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Operating Expenses for 13 consecutive years, with $182421.0 as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 26.01% to $182421.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $454658.0, a 23.25% decrease, with the full-year FY2025 number at $575101.0, down 12.03% from a year prior.
  • Operating Expenses was $182421.0 for Q3 2025 at Regen BioPharma, up from $99823.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $522931.0 in Q4 2022 to a low of $40398.0 in Q1 2021.
  • A 5-year average of $160714.3 and a median of $144768.0 in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 300.0% in 2021, then plummeted 65.23% in 2023.
  • Regen BioPharma's Operating Expenses stood at $165487.0 in 2021, then soared by 216.0% to $522931.0 in 2022, then tumbled by 65.23% to $181847.0 in 2023, then tumbled by 33.77% to $120443.0 in 2024, then skyrocketed by 51.46% to $182421.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Operating Expenses are $182421.0 (Q3 2025), $99823.0 (Q2 2025), and $172414.0 (Q1 2025).